Detalhe da pesquisa
1.
Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors.
Bioorg Med Chem Lett
; 22(15): 5114-7, 2012 Aug 01.
Artigo
Inglês
| MEDLINE | ID: mdl-22765900
2.
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
J Med Chem
; 60(7): 3002-3019, 2017 04 13.
Artigo
Inglês
| MEDLINE | ID: mdl-28287730
3.
Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.
J Med Chem
; 59(5): 2005-24, 2016 Mar 10.
Artigo
Inglês
| MEDLINE | ID: mdl-26756222
4.
Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors.
J Med Chem
; 48(4): 905-8, 2005 Feb 24.
Artigo
Inglês
| MEDLINE | ID: mdl-15715459
5.
Design, synthesis, and evaluation of NO-donor containing carbonic anhydrase inhibitors to lower intraocular pressure.
J Med Chem
; 58(6): 2821-33, 2015 Mar 26.
Artigo
Inglês
| MEDLINE | ID: mdl-25728019
6.
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
Cancer Cell
; 28(1): 70-81, 2015 Jul 13.
Artigo
Inglês
| MEDLINE | ID: mdl-26144315
7.
Positive allosteric modulator of the human 5-HT2C receptor.
Mol Pharmacol
; 64(1): 78-84, 2003 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-12815163
8.
2,3,4,5-tetrahydro- and 2,3,4,5,11,11a-hexahydro-1H-[1,4]diazepino[1,7-a]indoles: new templates for 5-HT(2C) agonists.
Bioorg Med Chem Lett
; 13(14): 2369-72, 2003 Jul 21.
Artigo
Inglês
| MEDLINE | ID: mdl-12824036